Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-692-4 | CAS number: 109-66-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
Skin sensitisation
Based on available data (Magnusson and Kligman Guinea-Pig Maximization tests (OECD TG 406)), Normal-Pentane is not considered to be a skin sensitiser.
Respiratory sensitisation
No data available
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study is classified as reliable without restriction because it is in compliance with the OCED principles of GLPs.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- GLP compliance:
- yes
- Type of study:
- not specified
- Justification for non-LLNA method:
- The sensitisation test used is a scientifically valid method equivalent or similar to OECD Guideline 406 for assessing skin sensitisation potential. As the data exists and is adequate for hazard assessment, performing a new LLNA test is not scientifically justified.
- Species:
- guinea pig
- Strain:
- Hartley
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Hazleton Research Products, Inc., Denver, Pennsylvania
- Age at study initiation: Approximately 6 weeks
- Weight at study initiation: 324 to 409 grams
- Housing: Individual (during test period) in suspended stainless steel cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 15 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18.33 to 21.67°C
- Humidity (%): 40 to 70%
- Photoperiod (hrs dark / hrs light): 12 hours dark and 12 hours light
IN-LIFE DATES: From: 1991-07-21 To: 1991-09-04 - Route:
- intradermal and epicutaneous
- Vehicle:
- other: Freund's Complete Adjuvant (FCA)
- Concentration / amount:
- Induction Phase: 5% n-pentane in ethanol (Site 2); 5% n-pentane in FCA/Water (Site 3)
Challenge Phase: 1% n-pentane in ethanol - Route:
- epicutaneous, occlusive
- Vehicle:
- other: Freund's Complete Adjuvant (FCA)
- Concentration / amount:
- Induction Phase: 5% n-pentane in ethanol (Site 2); 5% n-pentane in FCA/Water (Site 3)
Challenge Phase: 1% n-pentane in ethanol - No. of animals per dose:
- 20
- Details on study design:
- MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 6
- Test groups: FCA/Water; n-pentane in ethanol; n-pentane in FCA/Water
- Control group: FCA/Water; Ethanol; 5% Reverse Osmosis Water in FCA/Water
- Site: Mid-dorsal region, near the scapula
- Duration: 0 to 7 days
- Concentrations: same throughout
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 21
- Exposure period: 24 hours
- Test groups: n-pentane
- Control group: Ethanol
- Site: L Flank - n-pentane; R Flank - Carrier (ethanol)
- Concentrations: 1.0% n-pentane in ethanol
- Evaluation (hr after challenge): 24, 48
- Challenge controls:
- 0.4 mL of carrier - ethanol (100% ) was administered topically to guinea pigs in the treatment and irritation control groups
- Positive control substance(s):
- yes
- Remarks:
- 1-chloro-2,4-dinitrobenzene (DNCB)
- Positive control results:
- not reported
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 100% ethanol (0.4 mL)
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- No clinical signs observed
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 100% ethanol (0.4 mL). No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: No clinical signs observed.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 1% in ethanol
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- No treatment-related clinical signs observed
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 1% in ethanol. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: No treatment-related clinical signs observed.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 0.1% DNCB in acetone
- No. with + reactions:
- 15
- Total no. in group:
- 15
- Clinical observations:
- slight to severe erythema and edema were observed at 24 and 48 hours post challenge
- Remarks on result:
- other: see Remark
- Remarks:
- Reading: 1st reading. . Hours after challenge: 24.0. Group: positive control. Dose level: 0.1% DNCB in acetone. No with. + reactions: 15.0. Total no. in groups: 15.0. Clinical observations: slight to severe erythema and edema were observed at 24 and 48 hours post challenge.
- Interpretation of results:
- other: not sensitising
- Conclusions:
- n-Pentane showed no irritation or sensitization potential after intradermal and topical application in Guinea pigs (experimental days one and seven), followed by occluded dermal challenge on day 21. n-Pentane is not a dermal sensitiser.
- Executive summary:
A dermal sensitisation study was conducted in guinea pigs (20 females/dose; 15 females for positive control) using n-pentane.
Induction Phase: An area near the scapula in the mid-dorsal region of all animals was clipped on the day prior to intradermal injection of tbe test material and/or carrier. 6 intradermal injections (0.1 mL each) were administered to 3 different sites as follows: Site 1: FCA/water to treated and control groups; Site 2: 5.0% n-pentane in carrier (ethanol) to the treated group, 100% ethanol to the control group; Site 3: 5.0% n-pentane in FCA/Water to the treated group, 5.0% carrier (reverse osmosis water) in FCA/Water to the control group. On day 7 following injection, 0.5 mL of a mild to moderately irritating dose of n-pentane was administered topically over the previously injected areas and covered with occlusive wrapping. Control animals received topical carrier applications instead.
Challenge Phase: 21 days post induction phase, 0.1 mL of n-pentane (1.0% in ethanol) was applied topically to the left flank of both treated and control irritation groups. 0.4 mL of the carrier (ethanol) was applied to the right flank. All applications were kept secure under occlusive wrapping for 24 hours and animals observed for dermal effects for 48 hours.
Sensitization was evaluated by comparing the reactions of treated animals with the reactions of control animals that received a single epidermal exposure to the test material. Control responses were used to distinguish true sensitization from local irritation produced by the same concentration of test material.
All animals survived to study termination and displayed a weight gain from their day 0 values. Abnormal clinical observations during scheduled intervals were limited to one treated group animal that was emaciated and had a small amount of stool. Another animal exhibited slight emaciation and poor food consumption. Clinical signs observed in these two animals were considered to be correlated to the stress of the wrapping procedure and not treatment-related. No signs of dermal irritation were observed at any dose in either patch group. DNCB elicited positive reactions from all tested animals 24 and 48 hours after removal of the patch challenge.
Based on the lack of signs dermal irritation observed in the study, n-pentane is not considered a dermal sensitiser. This study was given a Klimisch score of 1 and classified as reliable without restriction because it is in compliance with the OCED principles of GLPs.
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1991-07-23 to 1991-09-04
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study is classified as reliable without restrictions because it is in compliance with the OECD principles of GLPs.
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in IUCLID Section 13.
- Reason / purpose for cross-reference:
- read-across: supporting information
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- yes
- Remarks:
- Information regarding the nature of the test material was not provided, but was noted to be the responsibility of the Sponsor. This deviation was not expected to affect the study results.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- Deviations:
- yes
- Remarks:
- Information regarding the nature of the test material was not provided, but was noted to be the responsibility of the Sponsor. This deviation was not expected to affect the study results.
- GLP compliance:
- yes
- Type of study:
- other: Not specified, but similar to the Guinea-pig Maximization test method, using Draize dermal scores and Freunds Complete Adjuvant (FCA)
- Justification for non-LLNA method:
- The sensitisation test used is a scientifically valid method that is equivalent or similar to the Guinea-pig Maximization test method and follows OECD Guideline 406 for assessing skin sensitisation potential. As the data exists and is adequate for hazard assessment, performing a new LLNA test is not scientifically justified.
- Species:
- guinea pig
- Strain:
- Hartley
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Hazleton Research Products, Inc., Denver, Pennsylvania
- Age at study initiation: approximately 6 weeks
- Weight at study initiation: 313 to 416 g
- Housing: individual, suspended stainless steel caging, indirect bedding
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): not reported
- Acclimation period: 15 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): maintained 18 to 22°C
- Humidity (%): maintained 40 to 70%
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12 hours dark and 12 hours light
IN-LIFE DATES: From: 1991-07-23 to 1991-09-04 - Route:
- other: intradermal at day 0 and epicutaneous, occlusive at day 7
- Vehicle:
- other: ethanol and reverse osmosis water
- Concentration / amount:
- Nominal: 5.0% at first induction, 100% at second induction, and 1.0% at challenge
Actual: 4.14% at first induction and 0.717% at challenge - Route:
- epicutaneous, occlusive
- Vehicle:
- other: ethanol and reverse osmosis water
- Concentration / amount:
- Nominal: 5.0% at first induction, 100% at second induction, and 1.0% at challenge
Actual: 4.14% at first induction and 0.717% at challenge - No. of animals per dose:
- 20; only 10 control animals used for challenge exposure
- Details on study design:
- MAIN STUDY
A. INDUCTION EXPOSURE
Day 0
- Exposure: intradermal
- Application: three pairs of injections
- Dose: 0.1 mL
- Test groups: exposed to FCA and test material
- Site 1: along spinal cord, near first thoracic vertebra; FCA/water
- Site 2: along spinal cord, near first thoracic vertebra; 5.0% test material in carrier
- Site 3: along spinal cord, caudal from first thoracic vertebra; 5.0% test material in FCA/water
- Control group: exposed to FCA and carrier
- Site 1: along spinal cord, near first thoracic vertebra; FCA/water
- Site 2: along spinal cord, near first thoracic vertebra; 100% carrier
- Site 3: along spinal cord, caudal from first thoracic vertebra; 5.0% carrier in FCA/water
Day 7
- Exposure: occlusive topical application
- Duration: 48 hours
- Dose: 0.5 mL
- Test groups: exposed to 100% test material
- Control group: exposed to 100% carrier
- Site: injected area on the dorsal surface
B. CHALLENGE EXPOSURE
Day 21
- Exposure: occlusive topical application
- Duration: 24 hours
- Dose: 0.4 mL
- Test groups: exposed to 1.0% test material in carrier on right flank, 100% carrier on left flank
- Control group: exposed to 1.0% test material in carrier on right flank, 100% carrier on left flank (10 animals only)
- Site: right and left flanks in the abdominal region
- Evaluation (hr after challenge): 24 and 48 hours after removal of challenge patches - Challenge controls:
- Control group responses were used to distinguish true sensitization from local irritation produced by a single exposure to the same concentration of test material. Test material was applied to the left flank of all treated and ten of the control group animals, while carrier alone was applied to the right flank of all treated and the same ten control group animals.
- Positive control substance(s):
- yes
- Remarks:
- 1 chloro-2,4-dinitrobenzene (DNCB)
- Positive control results:
- The positive control material (DNCB) elicited reactions from all 20 animals both at 24 and 48 hours after removal of the challenge patch. Based on these results, the animals and methods used are capable of detecting the sensitisation potential of the test material.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 1.0% test material (0.4 mL)
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No abnormal clinical observations were noted
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 1.0% test material (0.4 mL). No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No abnormal clinical observations were noted.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 1.0% test material (0.4 mL)
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- No abnormal clinical observations were noted
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 1.0% test material (0.4 mL). No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: No abnormal clinical observations were noted.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 0.1% DNCB (0.4 mL)
- No. with + reactions:
- 15
- Total no. in group:
- 15
- Clinical observations:
- -
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: positive control. Dose level: 0.1% DNCB (0.4 mL). No with. + reactions: 15.0. Total no. in groups: 15.0. Clinical observations: -.
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 1.0% test material (0.4 mL)
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No abnormal clinical observations were noted
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 1.0% test material (0.4 mL). No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: No abnormal clinical observations were noted.
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 1.0% test material (0.4 mL)
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- No abnormal clinical observations were noted
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 1.0% test material (0.4 mL). No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: No abnormal clinical observations were noted.
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 0.1% DNCB (0.4 mL)
- No. with + reactions:
- 10
- Total no. in group:
- 15
- Clinical observations:
- -
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: positive control. Dose level: 0.1% DNCB (0.4 mL). No with. + reactions: 10.0. Total no. in groups: 15.0. Clinical observations: -.
- Interpretation of results:
- other: not sensitising
- Conclusions:
- 2-methylbutane was considered non-irritating.
- Executive summary:
In this skin sensitisation study with isopentane young adult Hartley albino guinea pigs (20 females per dose) were tested using the Guinea Pig Maximization Test method. Guinea pigs were exposed to the test material via induction twice to allow for development of sensitisation, then challenged and compared to the control group and examined for signs of dermal irritation.
There was no evidence of dermal irritation or sensitisation in this study. 2 -methylbutane is not a dermal sensitizer. This study is classified with a Klimisch score of 1, reliable without restrictions, because it is in compliance with the OECD principles of GLP and because it is similar to OECD Guideline 406 and EU Method B.6.
- Endpoint:
- skin sensitisation: in vitro
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- an in vitro skin sensitisation study does not need to be conducted because adequate data from an in vivo skin sensitisation study are available
Referenceopen allclose all
Table 1. Incidence of Challenge in Guinea Pig - Ethanol |
||||||
Dermal Observation |
Dermal Score |
|||||
No. of animals |
0 |
1 |
2 |
3 |
4 |
|
Irritation Control Group |
||||||
24 hr erythema |
10 |
10 |
0 |
0 |
0 |
0 |
24 hr edema |
10 |
10 |
0 |
0 |
0 |
0 |
48 hr erythema |
10 |
10 |
0 |
0 |
0 |
0 |
48 hr edema |
10 |
10 |
0 |
0 |
0 |
0 |
Treatment Group |
||||||
24 hr erythema |
20 |
20 |
0 |
0 |
0 |
0 |
24 hr edema |
20 |
20 |
0 |
0 |
0 |
0 |
48 hr erythema |
20 |
20 |
0 |
0 |
0 |
0 |
48 hr edema |
20 |
20 |
0 |
0 |
0 |
0 |
Table 2. Incidence of Challenge in Guinea Pig – MRD-91-962 |
||||||
Dermal Observation |
Dermal Score |
|||||
No. of animals |
0 |
1 |
2 |
3 |
4 |
|
Irritation Control Group |
||||||
24 hr erythema |
10 |
10 |
0 |
0 |
0 |
0 |
24 hr edema |
10 |
10 |
0 |
0 |
0 |
0 |
48 hr erythema |
10 |
10 |
0 |
0 |
0 |
0 |
48 hr edema |
10 |
10 |
0 |
0 |
0 |
0 |
Treatment Group |
||||||
24 hr erythema |
20 |
20 |
0 |
0 |
0 |
0 |
24 hr edema |
20 |
20 |
0 |
0 |
0 |
0 |
48 hr erythema |
20 |
20 |
0 |
0 |
0 |
0 |
48 hr edema |
20 |
20 |
0 |
0 |
0 |
0 |
Table 3. Incidence of Challenge in Guinea Pig – DNCB (Positive Control) |
||||||
Dermal Observation |
Dermal Score |
|||||
No. of animals |
0 |
1 |
2 |
3 |
4 |
|
Irritation Control Group - Acetone |
||||||
24 hr erythema |
15 |
15 |
0 |
0 |
0 |
0 |
24 hr edema |
15 |
15 |
0 |
0 |
0 |
0 |
48 hr erythema |
15 |
15 |
0 |
0 |
0 |
0 |
48 hr edema |
15 |
15 |
0 |
0 |
0 |
0 |
Treatment Group – 0.1% DNCB in Acetone |
||||||
24 hr erythema |
15 |
0 |
0 |
9 |
6 |
0 |
24 hr edema |
15 |
6 |
5 |
4 |
0 |
0 |
48 hr erythema |
15 |
0 |
3 |
7 |
0 |
5 |
48 hr edema |
15 |
5 |
3 |
7 |
0 |
0 |
All animals survived to study termination and displayed a weight gain from their day 0 values. No abnormal clinical inlife observations were noted for any animals during the study. One control group animal displayed very slight erythema 24 hours following patch removal for the ethanol dose site. No other signs of dermal irritation were noted for either dose group on days 23 and 24. Based on the lack of signs of dermal irritation during the challenge phase of this study, isopentane shows no sensitization potential.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Skin sensitisation data is available for Normal-Pentane. Additionally, data is available for structural analogue, 2-methylbutane. This data is read across to Normal-Pentane based on analogue read across and a discussion and report on the read across strategy is provided as an attachment in IUCLID Section 13.
Normal-Pentane
A study was conducted using guinea pigs (20 females/dose; 15 females for positive control; Trimmer, 1991). For the induction phase, six intradermal injections (0.1 mL each) were administered to three different sites as follows: Site 1: FCA/water to treated and control groups; Site 2: 5.0% n-pentane in carrier (ethanol) to the treated group, 100% ethanol to the control group; Site 3: 5.0% n-pentane in FCA/Water to the treated group, 5.0% carrier (reverse osmosis water) in FCA/Water to the control group. On day 7 following injection, 0.5 mL of a mild to moderately irritating dose of n-pentane was administered topically over the previously injected areas and covered with occlusive wrapping. Control animals received topical carrier applications instead. The challenge phase was conducted 21 days post induction phase. n-Pentane (0.1 mL of n-pentane; 1.0% in ethanol) was applied topically to the left flank of both treated and control irritation groups. All animals survived to study termination and displayed a weight gain from their day 0 values. Abnormal clinical observations during scheduled intervals were limited to one treated group animal that was emaciated and had a small amount of stool. Another animal exhibited slight emaciation and poor food consumption. Clinical signs observed in these two animals were considered to be correlated to the stress of the wrapping procedure and not treatment-related. No signs of dermal irritation were observed at any dose in either patch group. DNCB elicited positive reactions from all tested animals 24 and 48 hours after removal of the patch challenge. Based on the lack of signs dermal irritation observed in the study, n-pentane was not considered a dermal sensitiser.
2-methylbutane
Young adult Hartley albino guinea pigs (20 females per dose) were tested using the Guinea Pig Maximization Test method (Trimmer et al., 1991). Guinea pigs were exposed to the test material via induction twice to allow for development of sensitisation, then challenged and compared to the control group and examined for signs of dermal irritation. There was no evidence of dermal irritation or sensitisation in this study. 2-Methylbutane is not a dermal sensitiser.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
There are no reports of respiratory sensitisation from Normal-Pentane in laboratory animals or in humans. However, the skin sensitisation study found no indication of skin sensitisation in guinea pigs. With these observations, it is presumed that Normal-Pentane will not be a respiratory sensitising agent.
Justification for classification or non-classification
Based on available data, Normal-Pentane does not meet the criteria for classification as a skin or respiratory sensitiser under the new Regulation (EC) 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)